Urakov Aleksandr Livievich,Ураков Александр Ливиевич,Sojkher Mikhail Grigorevich,Сойхер Михаил Григорьевич,Sojkher Marina Ivanovna,Сойхер Марина Ивановна,Reshetnikov Aleksej Petrovich,Решетников Алекс
申请号：
RU2014108586/15
公开号：
RU0002593344C2
申请日:
2014.03.05
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to dentistry, and can be used for treating bruxism. That is ensured by hardware determination tonic masseter straining, detecting among them muscles with pathological hypertonia, injection in each of them standard solution of botulinum toxin A and lantoksa in total a single dose up to 100 UNITS, the following control of efficiency and safety of injected drug owing to further analysis in face skin within a projection of these muscles dynamics of local temperature using infrared thermography and amplitude of potential amplifiers using surface electromyography during 3 weeks. Note here that before injection there is additional visualization with the help of ULTRASOUND muscle with pathological gipertonusom, before injection the solution is heated to + 37 °C, injection is performed in turn in every muscle under ultrasonic navigation, estimate accuracy and correctness injections of ultrasonic imaging localisation, size and shape of medicinal infiltrate appearing in tissues, safety injection is controlled additionally with the help of ULTRASOUND at duration of preservation and resorption postinjection medicamental infiltrate.EFFECT: invention enables recovering the function of masseter muscels and eliminating the myofascial pain syndrome with dysfunction of temporomandibular joint, due to increased accuracy of metering and injection into a local myorelaxant in each muscle with the help of ultrasonic navigation.1 cl, 1 exИзобретение относится к медицине, а именно к стоматологии, и может быть использовано для лечения бруксизма. Для этого проводят аппаратное определение тонического напряжения жевательных мышц, выявление среди них мышц, имеющих патологический гипертонус, инъекционное введение в каждую из них стандартного раствора ботулинического токсина А лантокса в суммарной разовой дозе до 100 ЕД, последующий контроль эффективности и безопасности введенного лекарства за счет последующего исследования в коже лиц
